Nautilus Biotechnology Inc
NAUT
Get informed when a big investor buys or sells
+ FollowMarket Cap$348.2M
Close$
$-0.14
105.4% downside
Current Fair Value
105.4% downsideOvervalued by 105.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $348.20 Million |
|---|---|
| Enterprise Value | $362.44 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.47 |
| Beta | 0.75 |
| Outstanding Shares | 126,634,782 |
Return
| Return on Equity | -39.53% |
|---|---|
| Return on Assets | -32.11% |
| Return on Invested Capital | -14.54% |
Valuation & Multiples
| P/E Ratio | -6.08 |
|---|---|
| PEG | 52.7 |
| Price to Sales | - |
| Price to Book Ratio | 2.58 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -14.71 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 5, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$250,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 61,700▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 43.04%▼ 3.15% |
|---|---|
| Total Invested | $210.83M▲ 85.47% |
| Investors Holding | 81▲ 15.00% |
ESG Score
No data